Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 41 Billion INR | -12.76% |
| 2022 | 47.4 Billion INR | -3.54% |
| 2021 | 49.14 Billion INR | 623.81% |
| 2020 | 6.78 Billion INR | 0.0% |
| 2019 | - INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 10.3 Billion INR | 2.04% |
| 2024 Q1 | 10.24 Billion INR | -4.66% |
| 2023 Q2 | 10.11 Billion INR | -5.39% |
| 2023 FY | 41.35 Billion INR | -12.76% |
| 2023 Q4 | 10.74 Billion INR | 11.87% |
| 2023 Q3 | 9.6 Billion INR | -5.01% |
| 2023 Q1 | 10.68 Billion INR | -5.38% |
| 2022 Q2 | 12.98 Billion INR | 12.04% |
| 2022 Q1 | 11.59 Billion INR | -9.13% |
| 2022 FY | 47.4 Billion INR | -3.54% |
| 2022 Q4 | 11.29 Billion INR | -2.01% |
| 2022 Q3 | 11.52 Billion INR | -11.27% |
| 2021 FY | 49.14 Billion INR | 623.81% |
| 2021 Q4 | 12.75 Billion INR | -0.56% |
| 2021 Q3 | 12.83 Billion INR | 5.42% |
| 2021 Q2 | 12.17 Billion INR | 6.9% |
| 2021 Q1 | 11.38 Billion INR | 67.68% |
| 2020 Q4 | 6.78 Billion INR | 200.0% |
| 2020 Q3 | -6.78 Billion INR | -159.64% |
| 2020 Q2 | 11.38 Billion INR | 0.0% |
| 2020 FY | 6.78 Billion INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 72.211% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | -476.231% |
| Concord Biotech Limited | 9.98 Billion INR | -310.843% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | -56.759% |
| Lyka Labs Limited | 1.05 Billion INR | -3800.271% |
| Panacea Biotec Limited | 5.59 Billion INR | -633.309% |
| Piramal Pharma Limited | 81.71 Billion INR | 49.818% |
| SMS Lifesciences India Limited | 3.05 Billion INR | -1240.197% |
| Supriya Lifescience Limited | 5.7 Billion INR | -618.91% |
| Syngene International Limited | 34.88 Billion INR | -17.538% |
| TAKE Solutions Limited | 656.08 Million INR | -6149.916% |
| Zota Health Care Limited | 1.8 Billion INR | -2171.859% |